SUPN · Supernus Pharmaceuticals, Inc. - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · SUPN

1Y 3Y 5Y Max

Annual Quarterly

Income Statement

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$718.95M	$661.82M	$607.52M◇	$667.24M	$579.77M	$520.40M
Cost of Revenue	$74.56M	$77.91M	-	-	-	$52.46M
Gross Profit	$644.39M	$583.91M	-	-	-	$467.94M
R&D	$106.23M	$108.80M	$91.59M◇	$74.55M	$90.47M	$75.96M
SG&A	$485.56M	$321.58M	$336.36M◇	$377.22M	$304.76M	$200.68M
Total Operating Expenses	$781.24M	$580.15M	-	$621.11M	$493.75M	$346.70M
D&A	$91.56M	$80.41M	-	$85.54M	$32.59M	$18.14M
Operating Income	($62.28M)	$81.67M	($5.27M)◇	$46.12M	$86.03M	$173.70M
Interest Expense	$0	$0	-	$19.43M	$19.70M	$19.43M
Income Tax	($10.48M)	$24.00M	$1.45M◇	$32.0K	$19.75M	$41.70M
Net Income	($38.55M)	$73.86M	$1.32M◇	$60.71M	$53.42M	$126.95M
EPS - Basic	($0.68)	$1.34	$0.02◇	$1.13	$1.01	$2.41
EPS - Diluted	($0.68)	$1.32	$0.02◇	$1.04	$0.98	$2.36

Balance Sheet

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Cash & Equivalents	$128.45M	$69.33M	$75.05M◇	$93.12M	$203.43M	$288.64M
Accounts Receivable	$187.80M	$142.08M	-	$165.50M	$148.93M	$140.88M
Inventory	$112.48M	$54.29M	-	$91.54M	$85.96M	$48.33M
Accounts Payable	$2.68M	$4.59M	-	$10.54M	$9.33M	$6.15M
Current Assets	$644.18M	$686.07M	$493.11M◇	$734.15M	$601.59M	$630.42M
Total Assets	$1.45B	$1.37B	$1.28B◇	$1.70B	$1.69B	$1.50B
Current Liabilities	$338.17M	$292.40M	$290.20M◇	$687.96M	$315.38M	$245.11M
Long-term Debt	-	-	-	-	-	-
Total Liabilities	$390.93M	$332.34M	$356.16M◇	$816.30M	$873.30M	$759.24M
Stockholders' Equity	$1.06B	$1.04B	($593.0K)◇	$886.20M	$815.85M	$744.86M
Retained Earnings	$517.88M	$556.43M	-	$481.25M	$379.92M	$326.50M

Cash Flow

Line item	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Operating Cash Flow	$47.33M	$171.95M	$111.08M◇	$116.83M	$127.13M	$138.40M
Investing Cash Flow	$4.11M	($189.87M)	$268.73M◇	($216.66M)	($81.91M)	($34.70M)
Financing Cash Flow	$9.13M	$12.19M	($397.88M)◇	($10.48M)	($130.42M)	$3.56M
CapEx	$1.34M	$725.0K	$551.0K◇	$412.0K◇	-	$3.45M
Free Cash Flow	$45.99M	$171.23M	$110.53M◇	$116.41M◇	-	$134.95M

Ratios

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Profitability
Gross margin	89.6%	88.2%	-	-	-	89.9%
Operating margin	-8.7%	12.3%	-0.9%	6.9%	14.8%	33.4%
EBITDA margin	4.1%	24.5%	-	19.7%	20.5%	36.9%
Net margin	-5.4%	11.2%	0.2%	9.1%	9.2%	24.4%
Free cash flow margin	6.4%	25.9%	18.2%	17.4%	-	25.9%
FCF / Net income	-1.19	2.32	83.99	1.92	-	1.06
R&D / Revenue	14.8%	16.4%	15.1%	11.2%	15.6%	14.6%
SG&A / Revenue	67.5%	48.6%	55.4%	56.5%	52.6%	38.6%
Effective tax rate	-	24.5%	52.5%	0.1%	27.0%	24.7%
Return on assets	-2.7%	5.4%	0.1%	3.6%	3.2%	8.4%
Return on equity	-3.6%	7.1%	-221.9%	6.9%	6.5%	17.0%
Return on invested capital	-	-	-	-	-	-
Liquidity
Current ratio	1.90	2.35	1.70	1.07	1.91	2.57
Quick ratio	1.57	2.16	1.70	0.93	1.63	2.37
Cash ratio	0.38	0.24	0.26	0.14	0.65	1.18
Leverage
Debt / Equity	-	-	-	-	-	-
Debt / Assets	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-
Interest coverage	-	-	-	2.4x	4.4x	8.9x
Equity multiplier	1.37	1.32	-2154.59	1.92	2.07	2.02
Liabilities / Assets	0.27	0.24	0.28	0.48	0.52	0.50
Efficiency
Asset turnover	0.49	0.48	0.48	0.39	0.34	0.35
Inventory turnover	0.66	1.43	-	-	-	1.09
Days sales outstanding	95d	78d	-	91d	94d	99d
Days inventory outstanding	551d	254d	-	-	-	336d
Days payable outstanding	13d	21d	-	-	-	43d
Cash conversion cycle	633d	311d	-	-	-	392d
Valuation
P / E	-	27.4x	1447.0x	34.3x	29.8x	10.7x
P / B	2.6x	2.0x	-	2.5x	1.9x	1.8x
P / S	3.9x	3.1x	2.6x	3.3x	2.7x	2.6x
EV / EBITDA	91.4x	12.1x	-	16.0x	11.6x	5.5x
Growth
Revenue growth (YoY)	8.6%	8.9%	-8.9%	15.1%	11.4%	32.5%
Revenue CAGR (3y)	2.5%	4.5%	5.3%	19.3%	12.3%	19.9%
Revenue CAGR (5y)	6.7%	11.0%	8.2%	17.2%	21.9%	29.2%
Gross profit growth (YoY)	10.4%	-	-	-	-	24.4%
Operating income growth (YoY)	-	-	-	-46.4%	-50.5%	16.9%
Net income growth (YoY)	-	5512.8%	-97.8%	13.6%	-57.9%	12.3%
EPS growth (YoY)	-	6500.0%	-98.1%	6.1%	-58.5%	12.4%
EPS CAGR (3y)	-	10.4%	-79.6%	-20.9%	-21.8%	29.8%
EPS CAGR (5y)	-	-8.9%	-60.4%	-0.8%	-11.1%	53.2%
FCF growth (YoY)	-73.1%	54.9%	-5.1%	-	-	-3.9%
FCF CAGR (5y)	-19.4%	4.1%	-2.9%	12.4%	-	35.1%
Book value growth (YoY)	2.5%	-	-	8.6%	9.5%	25.1%

Sales by segment

From XBRL dimensional facts in the 10-K period ending 2025-12-31.

Business segments

$718.95M total

Reportable Segment$718.95M · 100.0%

Product / service

$1.35B total

Product$626.54M · 46.6%

Qelbree$304.65M · 22.6%

GOCOVRI$146.82M · 10.9%

Collaboration Revenue$53.00M · 3.9%

APOKYN$47.77M · 3.6%

Trokendi Xr$42.42M · 3.2%

Oxtellar XR$40.70M · 3.0%

Royalty License And Other Revenue$39.42M · 2.9%

Manufactured Product Other$26.91M · 2.0%

ONAPGO$17.25M · 1.3%

Stability scores

Altman Z′

FY 2025 · bankruptcy risk

1.95

Grey zone

Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.

Piotroski F-score

FY 2025 · 9-point quality

5/9

Neutral

✗Net income positive
✓Operating cash flow positive
✗ROA improved YoY
✓Cash flow > net income
-Long-term debt decreased
✗Current ratio improved
✓No share dilution
✓Gross margin improved
✓Asset turnover improved

Peer comparison

Same SIC group: Pharmaceutical Preparations

Company	Revenue (last FY)	Net margin	ROE
LLY	$65.18B	31.7%	77.8%
UTHR	$3.18B	41.9%	18.8%
PFE	$62.58B	12.4%	9.0%
ZTS	$9.47B	28.2%	80.2%
VRTX	$12.00B	32.9%	21.2%

Comparing SUPERNUS PHARMACEUTICALS against the 5 most active filers in the same SIC group.

Cells marked with a small ◇ are sourced from SEC's bulk Financial Statement Data Sets, which can lose dimensional context (notably Revenue and Operating Income for issuers that report by segment). These cells will be replaced with authoritative values from the Company Facts API as the backfill completes.